CD30-targeted therapy with brentuximab vedotin and DLI in a patient with T-cell posttransplantation lymphoma: induction of clinical remission and cellular immunity

Transplantation. 2013 Aug 15;96(3):e16-8. doi: 10.1097/TP.0b013e31829a9258.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Brentuximab Vedotin
  • Female
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Humans
  • Immunity, Cellular*
  • Immunoconjugates / therapeutic use*
  • Ki-1 Antigen / antagonists & inhibitors*
  • Lymphocyte Transfusion*
  • Lymphoma, T-Cell / drug therapy*
  • Lymphoma, T-Cell / etiology
  • Lymphoma, T-Cell / immunology
  • Remission Induction
  • Transplantation, Homologous

Substances

  • Immunoconjugates
  • Ki-1 Antigen
  • Brentuximab Vedotin